In our study, we aimed to investigate the relationship between anti-müllerian hormone (AMH) and Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) score, which are known to be increased in patients with polycystic ovary syndrome (PCOS), and morning blood pressure surge (MBPS), and whether these measurements are a marker for early cardiovascular disease risk in patients with PCOS. Forty patients aged between 18 and 65 years with hypertension (HT) and PCOS, 40 patients with HT but without PCOS, and 40 people representing the healthy control group were included in our prospective, cross-sectional study. All patients underwent ambulatory blood pressure measurement for 24 hours and MBPS was calculated. The study groups were divided into 3 groups as healthy control group (group 1), patient group with HT without PCOS (group 2), and patient group with HT and PCOS (group 3). MBPS was found to be statistically significantly higher in group 3. In linear regression analysis, AMH and HOMA-IR levels were found to be independently associated with MBPS. In patients with PCOS, AMH, and HOMA-IR levels were significantly higher in the group with MBPS > 25 mm Hg. Early diagnosis and treatment of PCOS and accompanying comorbidities can halt the progression of cardiac disorders and reduce cardiovascular mortality and morbidity. AMH level, HOMA-IR score, and MBPS measurement can be used in early detection and prediction of cardiovascular disease in PCOS patients.
Insulin-like growth factor-1 (IGF-1) and growth hormone release is elevated in acromegaly, a chronic condition. Our objective was to study the correlation between carotid femoral pulse wave velocity (CF-PWV) and galectin-3 level in acromegaly patients. This protein is believed to alter in response to early inflammation and atherosclerosis. Our study was planned as a prospective, single-center cross-sectional study. Our study comprised 40 healthy controls and 40 newly diagnosed acromegaly patients ranging in age from 18 to 65 years old at Adana City Training and Research Hospital. The patients’ IGF-1, growth hormone, hemogram, and biochemistry values were assessed. Human galectin-3 kits and the Enzyme-Linked Immunosorbent Assay were used to measure the amount of galectin-3. Patients underwent CF-PWV assessments with the use of Doppler ultrasonography and concurrent electrocardiography. Our investigation indicated that acromegaly patients had greater levels of the fibrosis and inflammation indicator galectin-3 as well as the gold standard indication of arterial stiffness, CF-PWV. We observed a link between blood galectin-3 level and both IGF-1 level and CF-PWV measures in the correlation analysis. Galectin-3 has the potential to be a novel biomarker for the diagnosis and prognosis of cardiovascular disease in acromegaly patients, as well as a therapeutic target for the development of this disease.
Aim: Diabetes mellitus (DM) is associated with the development and progression of metabolic dysfunction-associated steatotic liver disease (MASLD). In our study, we aimed to evaluate the findings of MASLD and fibrosis according to liver ultrasound (USG) imaging, FIB-4 score and fibroscan findings in patients with type 2 DM followed in our internal medicine clinic. Methods: In our retrospective and cross-sectional study, 1282 patients diagnosed with type 2 DM whose anamnesis and previous examinations did not constitute an obstacle for inclusion in the study were included. The abdominal USG imaging of the patients were analysed from the system and the FIB-4 score was calculated. Liver stiffness (LS) measurements were performed with FibroScan® Mini 430 device (Echosens, France). Results: USG imaging was performed in 474 (36.9%) of 1282 patients and MASLD was diagnosed in 341 (71.9%) of these patients. FIB-4 score> was 1.3 in 45 of 341 patients diagnosed with MASLD. Fibroscan imaging was performed in 231 of 341 patients with MASLD. In 52 (22.5%) of 231 patients, LS measurements> were 8 kPa Conclusion: We recommend early screening of MASLD, which is associated with advanced fibrosis and increased cardiovascular mortality and morbidity in patients with DM, with liver USG, measurement of FIB-4 score and evaluation of LS with fibroscan in centres where possible.
30 June 2025 in Cukurova Anestezi ve Cerrahi Bilimler Dergisi
Aim: Contrast-induced acute kidney injury (CI-AKI) is associated with increased risk of morbidity and mortality and specific treatments are needed. In our study, we aimed to investigate the association of sodium-glucose cotransporter-2 inhibitors (SGLT2-I) use with the development of CI-AKI due to coronary angiography (CAG) in patients with DM. Methods: A total of 516 type 2 diabetes mellitus (DM) patients, including 250 SGLT2-I users and 266 non-SGLT2-I users, were included in our retrospective and cross-sectional study. Results: The study groups were divided into CI-AKI (+) and CI-AKI (-). SGLT2-I use was statistically significantly higher in the CI-AKI (-) group. Multivariate logistic regression analysis showed that SGLT2-I use reduced the probability of CI-AKI by 83.8%. Conclusion: Our findings suggest that SGLT2-Is may significantly reduce the risk of CI-AKI in diabetic patients undergoing CAG. In conclusion, the use of SGLT2-I may have a protective and preventive effect against the development of CI-AKI.
Patients with primary hyperparathyroidism (PHPT) are known to have structural and functional changes in the vascular system. Bioactive peptides associated with the apelinergic system play a role in ischemic heart disease and atherosclerosis. In this study, we aimed to investigate the changes in serum elabela, a novel apelinergic system peptide, and its relationship with aortic intima media (AIM) measurements in patients with newly diagnosed primary hyperparathyroidism. The study was prospectively conducted with 45 patients with newly diagnosed Primary Hyperparathyroidism who were admitted to the Internal Medicine outpatient clinics of Adana City Training and Research Hospital. Forty people with similar demographic characteristics were included as a healthy control group. Hemogram, biochemistry, parathormone, vitamin D, urinary calcium, dual x-ray absorptiometry (DEXA), Elabela and aortic intima media levels were measured. The study groups were divided into three groups: healthy control group (Group 1: 40 patients), PHPT group without surgical indication (Group 2: 20 patients) and PHPT group with surgical indication (Group 3: 25 patients). Elabela level was found to increase from group 1 to group 3. It was 2.1 (1.3–2.4) ng/mL in group 1, 10.45 (3.7-14.15) ng/mL in group 2 and 12.6 (12.0–14.0) ng/mL in group 3 (p < 0.001). AIM level was found to be statistically significantly higher in group 3 compared to groups 1 and 2. It was 1.2 (1.0-1.4) mm in group 1, 1.3 (1.2–1.6) mm in group 2 and 2.15 (1.95–2.32) mm in group 3 (p < 0.001). Linear regression analysis performed with the parameters significantly correlated with Elabela in group 3 showed that DEXA and AIM levels were independently associated with Elabela. In the multivariate logistic regression analysis performed for the independent determination of patients with surgical indication in the patient group, it was found that Elabela level independently determined the group with surgical indication. According to this analysis, each 1 unit increase in Elabela level increased the probability of surgery by 30.9% in the patient group. In patients with primary hyperparathyroidism, serum Elabela level may be increased due to activation of the Apelinergic system in response to adverse vascular and cardiac effects that may be caused by increased parathormone. Elabela level can be used to determine the indication for surgery in PHPT patients.
Background: Diabetic retinopathy (DR) is the most prevalent microvascular complication of type 2 diabetes mellitus (T2DM) and a recognised marker of systemic vascular injury. Whether DR—graded independently by two experienced ophthalmologists as part of routine institutional care—is independently associated with concurrent nephropathy (urine albumin-to-creatinine ratio [UACR] ≥ 30 mg/g) and subclinical cardiac stress (N-terminal pro-B-type natriuretic peptide [NT-proBNP] ≥ 125 pg/mL) remains insufficiently examined. Methods: Retrospective cross-sectional study of 401 T2DM adults who underwent dilated fundus examination independently graded by two board-certified ophthalmologists (each ≥ 10 years’ experience in diabetic eye disease) using ETDRS-based classification. Inter-physician agreement was quantified by Cohen’s weighted kappa. The primary composite outcome was concurrent nephropathy and subclinical cardiac stress. Multivariable logistic regression adjusted for age, sex, HbA1c, diabetes duration, eGFR, hypertension, and pharmacological treatments. Results: The composite outcome was present in 120 (64.2%) DR-positive vs. 14 (6.5%) DR-negative patients (crude OR: 25.59 (13.78–47.51); p < 0.001; fully adjusted OR: 21.49 (11.02–41.81); p < 0.001). Inter-physician agreement was high (Cohen’s weighted κ = 0.88; 95% CI: 0.83–0.93). Nephropathy alone was found in 164 (87.7%) vs. 76 (35.5%) patients (OR: 12.95 (7.71–21.75); p < 0.001), and elevated NT-proBNP in 137 (73.3%) vs. 39 (18.2%) patients (OR: 12.29 (7.65–19.76); p < 0.001). A significant trend across DR severity grades was observed (p for trend < 0.001), although the gradient was not strictly monotonic. ROC AUC = 0.837 (95% CI: 0.784–0.860). Conclusions: Ophthalmologist-graded DR was independently associated with the concurrent presence of albuminuria and elevated NT-proBNP in T2DM. Because the design is cross-sectional, these findings describe association rather than prediction or causation. They generate the hypothesis that retinal grading may help flag patients in whom cardiorenal biomarker assessment is worth considering, but prospective validation is required before any screening application.